My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 624 / https://doi.org/10.3332/ecancer.2016.624

Clinical Study

Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience

Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of progression was found in pts with elevated LDH, ECOG PS >1 and more than two metastatic sites. Grade 3–4 adverse events were recorded in 4 pts. In this retrospective analysis, Dabrafenib confirmed its role as the standard clinical option in metastatic melanoma pts.

Keywords: metastatic melanoma, Dabrafenib, BRAF V600 mutation, target therapy

Categories:

Melanoma & skin

Loading Article Metrics ... Please wait

Related articles

Case Report: Volumetric arc therapy for total scalp irradiation: case report for a recurrent basal cell carcinoma of the scalp

Abstract | Full Article | PDF Published: 11 May 2017 / https://doi.org/10.3332/ecancer.2017.737

Case Report: Penile melanoma: a 20-Year analysis of six patients at the National Cancer Institute of Peru, Lima

Abstract | Full Article | PDF | Spanish Published: 04 Apr 2017 / https://doi.org/10.3332/ecancer.2017.731

Conference Report: Highlights from the first ecancer–Liga Colombiana contra el Cancer conference, 17–18 November 2016, Bogota, Colombia

Abstract | Full Article | PDF | Spanish Published: 28 Mar 2017 / https://doi.org/10.3332/ecancer.2017.730

Conference Report: Cancer Immunotherapy: from the lab to clinical applications. Potential impact on cancer centres’ organisation

Abstract | Full Article | PDF Published: 09 Nov 2016 / https://doi.org/10.3332/ecancer.2016.691

Research: Postoperative radiotherapy in the management of keloids

Abstract | Full Article | PDF | Spanish Published: 08 Nov 2016 / https://doi.org/10.3332/ecancer.2016.690



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence